





# The Innovative Medicines Initiative Socio-economic impacts

Pierre Meulien, IMI Executive Director  
European Innovation Summit • European Parliament • 08.12.2015

# Challenges in medicines development



# IMI – Europe's partnership for health



# IMI 2 Strategic Research Agenda

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines



The right prevention and treatment  
for the right patient at the right time  
Strategic Research Agenda for  
Innovative Medicines Initiative 2

**Aligned with  
WHO priorities**

# IMI socio-economic impacts – some numbers

**2 272 FTE jobs**  
directly associated  
with IMI projects

**460+ biological marker  
candidates** for better  
diagnosis & treatment

**169 SMEs**

**25+ new tools**  
to facilitate drug  
development

**13 spin-offs**

**1 134 scientific  
publications**

**20 patent  
applications**

**65 clinical studies**

# When pharmaceutical companies share data & collaborate with unis & SMEs...

## The problem


Often, researchers only discover that a potential medicine is **toxic to a vital organ** (e.g. heart, kidneys, liver...) very late in drug development...

**after they have invested significant time and money in it!**


## The eTOX solution

A computer tool to detect toxicity issues early in drug development

**Input = 2D**  
structure of a possible drug




**Output =**  
possible effect  
on heart – ECG  
result!



# Birth of a successful new organisation – the Open PHACTS Foundation

Data & facts from multiple public sources



**Open PHACTS  
Discovery Platform +  
apps**



Makes it easier to find & analyse info for drug research

- Platform success → **Open PHACTS Foundation** created
- Foundation now a partner in **two Horizon 2020 projects**
- Expertise in linking data, data interoperability, etc.

## Big Data Europe

Aim: integrate existing big data infrastructures → interoperable, large-scale, multi-lingual data assets.

## EU-ToxRisk

Aim: achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment.


# European Lead Factory – breathing new life into drug discovery programmes

The project combines...

- the **innovation** of academia,
- the **agility** of SMEs,
- the **experience** of pharma.
- **funding** from the EU
- **an award-winning IP model**

*"Access to the European Lead Factory has fast-forwarded our drug discovery programme in the field of oncology by several years."*

*Huib Ovaa, Netherlands Cancer Institute*





# IMI Ebola+ programme – building infrastructures for local communities

**Kambia,  
Sierra Leone**

**Vaccine  
storage  
facility** built to  
facilitate  
clinical trial of  
Ebola vaccine

**Local staff**  
also benefit  
from training



# A quick quiz

**The answer  
is 17 years**

**What is the  
question?**



# Take home messages

Oldest IMI projects = 6 years! The fact we are already having an impact demonstrates **success of PPP model**

IMI allows **unprecedented collaboration** amongst pharmaceutical companies

IMI is delivering results that could not be achieved through other programmes and represents **good value for money** for Europe

In IMI projects, **all partners benefit** from networking, new knowledge, new opportunities, new tools and resources

In health research, IMI is a unique, successful initiative that **Europe can be proud of**

# Stay in touch

- Visit our website  
[www.imi.europa.eu](http://www.imi.europa.eu)
- Sign up to our newsletter  
[bit.ly/IMInewsletter](http://bit.ly/IMInewsletter)
- Follow us on Twitter  
[@IMI\\_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group  
[bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)
- E-mail us  
[infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)



- Home
- About IMI
- Ongoing projects
- Calls for proposals
- News, Events & Media
- Reference documents

- PARTNER SEARCH
- EDUCATION & TRAINING
- SMALL & MEDIUM-SIZED ENTERPRISES
- INTELLECTUAL PROPERTY

**THE INNOVATIVE MEDICINES INITIATIVE**  
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.  
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.  
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

**IMI LAUNCHES EBOLA+ PROGRAMME**  
IMI has launched an ambitious programme to accelerate the development of **vaccines and treatments** against **Ebola and related diseases**. The first Call under the Ebola+ programme has a total budget of €280m.

**IMI NEWSFLASH**

**10/11/2014** : Got questions about IMI's #Ebola programme? Check the FAQs and sign up to our webinars on 12/11 and 17/11 <http://t.co/gaZFnWZk1a>

**06/11/2014** : IMI #Ebola Topic 5: rapid #diagnostic tests that work in the real world <http://t.co/gaZFnWZk1a>

**06/11/2014** : IMI #Ebola Topic 4: using technology to promote #vaccine compliance <http://t.co/gaZFnWZk1a>

Follow us on Twitter

**NEWSLETTER**  
Read & subscribe more

**AGENDA**

- 03/12/2014 - C-Path and IMI 2nd Annual Meet...
- 26/11/2014 - Bringing health-related life s...
- 18 - 18/11/2014 - Financial Management Workshop ...

more





**Thank you**

Pierre Meulien  
IMI Executive Director

[www.imi.europa.eu](http://www.imi.europa.eu)

 @IMI\_JU